Exin Therapeutics
AI drug discovery platform for neurotherapeutics
About
We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding. Exin Therapeutics is a Y Combinator company (Winter 2025). YC-listed status: Active.
- Website
- exintherapeutics.com
- Location
- San Francisco, CA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Exin Therapeutics — AI-driven target discovery platform for neurotherapeutics that predicts drug candidate potential across multiple neural disorders simultaneously. · Other
Links
- Y Combinator profileycombinator